DE69923976D1 - Verwendung eines tiermodells, das p53-defizient ist und dessen erinnerungsvermögen und/oder verhalten gestört ist, zur entwicklung von therapeutika - Google Patents

Verwendung eines tiermodells, das p53-defizient ist und dessen erinnerungsvermögen und/oder verhalten gestört ist, zur entwicklung von therapeutika

Info

Publication number
DE69923976D1
DE69923976D1 DE69923976T DE69923976T DE69923976D1 DE 69923976 D1 DE69923976 D1 DE 69923976D1 DE 69923976 T DE69923976 T DE 69923976T DE 69923976 T DE69923976 T DE 69923976T DE 69923976 D1 DE69923976 D1 DE 69923976D1
Authority
DE
Germany
Prior art keywords
deficient
memory
therapeutics
disturbed
behavior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69923976T
Other languages
English (en)
Other versions
DE69923976T2 (de
Inventor
Robert Amson
Jean-Michel Lassalle
Adam Telerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR ENGINES LAB PARIS
Original Assignee
MOLECULAR ENGINES LAB PARIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR ENGINES LAB PARIS filed Critical MOLECULAR ENGINES LAB PARIS
Application granted granted Critical
Publication of DE69923976D1 publication Critical patent/DE69923976D1/de
Publication of DE69923976T2 publication Critical patent/DE69923976T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Surgical Instruments (AREA)
  • Image Generation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69923976T 1998-08-05 1999-07-26 Verwendung eines tiermodells, das p53-defizient ist und dessen erinnerungsvermögen und/oder verhalten gestört ist, zur entwicklung von therapeutika Expired - Fee Related DE69923976T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810076 1998-08-05
FR9810076A FR2781979B1 (fr) 1998-08-05 1998-08-05 Modele animal presentant une deficience de la memoire et/ou des troubles comportementaux
PCT/FR1999/001828 WO2000007438A1 (fr) 1998-08-05 1999-07-26 Utilisation d'un modele animal deficient en p53 et presentant une deficience de la memoire et/ou des troubles comportementaux a des fins therapeutiques

Publications (2)

Publication Number Publication Date
DE69923976D1 true DE69923976D1 (de) 2005-04-07
DE69923976T2 DE69923976T2 (de) 2006-04-06

Family

ID=9529432

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923976T Expired - Fee Related DE69923976T2 (de) 1998-08-05 1999-07-26 Verwendung eines tiermodells, das p53-defizient ist und dessen erinnerungsvermögen und/oder verhalten gestört ist, zur entwicklung von therapeutika

Country Status (8)

Country Link
US (1) US6921845B1 (de)
EP (1) EP1102530B1 (de)
JP (1) JP2002521073A (de)
AT (1) ATE289748T1 (de)
CA (1) CA2339876A1 (de)
DE (1) DE69923976T2 (de)
FR (1) FR2781979B1 (de)
WO (1) WO2000007438A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186879B2 (en) * 2000-09-21 2007-03-06 Baylor College Of Medicine Screening systems and methods for identifying modulators of xenobiotic metabolism
CA2422921A1 (en) * 2000-09-21 2002-03-28 David D. Moore Screening systems and methods for identifying modulators of xenobiotic metabolism
US7094948B2 (en) * 2001-11-14 2006-08-22 Astellas Pharma, Inc. Transgenic animals
US7705198B2 (en) 2006-05-10 2010-04-27 Board Of Regents Of The University Of Nebraska KSR2 knockout mice and methods of use thereof
US7723564B2 (en) 2006-05-10 2010-05-25 Board Of Regents Of The University Of Nebraska Compositions and methods for modulation of KSR1 and KSR2 interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503967A (ja) * 1991-01-04 1994-05-12 ベイラー・カレッジ・オブ・メディシン 腫瘍感受性非ヒト動物
FR2710846B1 (fr) * 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death

Also Published As

Publication number Publication date
ATE289748T1 (de) 2005-03-15
WO2000007438A1 (fr) 2000-02-17
FR2781979B1 (fr) 2001-06-08
EP1102530A1 (de) 2001-05-30
DE69923976T2 (de) 2006-04-06
CA2339876A1 (fr) 2000-02-17
JP2002521073A (ja) 2002-07-16
EP1102530B1 (de) 2005-03-02
US6921845B1 (en) 2005-07-26
FR2781979A1 (fr) 2000-02-11

Similar Documents

Publication Publication Date Title
Ahlstrom The interpretation of archaeological tree-ring dates
Miner A Review of the Literature on the Nature and Control of Odors from Pork Production Facilities: Bibliography
Gadzama Attenuation of the effects of desertification through sustainable development of Great Green Wall in the Sahel of Africa
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
Wohlwill et al. Environment and the social sciences: Perspectives and applications.
Round Feedback effects in interregional input-output models: What have we learned?
Benitez et al. Historical land-cover conversion (1665–1820) in the Choptank watershed, eastern United States
DE69923976D1 (de) Verwendung eines tiermodells, das p53-defizient ist und dessen erinnerungsvermögen und/oder verhalten gestört ist, zur entwicklung von therapeutika
DE60317392D1 (de) Verfahren zur automatischen Aktualisierung des Pfadzugriffs zu einem Festplattensystem eines Hardwareperimeters von Rechnerressourcen, Anordnung zur Durchführung dieses Verfahrens und Speicher, der in diesem System verwendet wird
Bethke et al. Dogs: archaeology beyond domestication
DE69708057D1 (de) Verfahren zur verwendung eines computers zum verwalten des informationsaustausches zum erstellen von formularen
Hull et al. Tendons and ligaments of the Rangifer tarandus metapodial and hoof
DE60119352D1 (de) System und methode zum zugriff und zur organisation von in einem netzwerk verfügbaren information
ATE362993T1 (de) Verfahren zur entwicklung von pdk1-modulatoren
Michelson Public policy in temporal perspective
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
Gade The influence of basic design variables on the acoustics of concert halls; new results derived from analysing a large number of existing halls
Kondaparthi et al. Identification of Novel Molecular Scaffolds as Inhibitors of SP2 Protein-An Insilico Approach
ATE342372T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
Swallow Artificial selection for high voluntary activity in house mice: a study in evolutionary physiology
ATE349544T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
Habibi et al. Investigation of the Relation between Memorability and Social Collaboration in Regeneration of Urban Identity, Case Study: Shahrdari Square in Rasht
DE69216236D1 (de) Mittel zur abwehr von tieren, verfahren zu ihrer herstellung und ihre verwendung
DE60303296D1 (de) Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten
Lee et al. Effect of drinking and smoking on skin health and make-up

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee